Assembling intelligence…
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
| Company | Orders | Obligated | Latest order end |
|---|---|---|---|
| UNIVERSITY OF OKLAHOMA | 2 | $2.0M | 2028-03-24 |
| 75N91025F00001 UNIVERSITY OF OKLAHOMA · National Institutes of Health | $1.2M | 2028-03-24 |
| 75N91024F00002 UNIVERSITY OF OKLAHOMA · National Institutes of Health | $761K | 2026-06-16 |